Occurrence and predictors of acute stent recoil-A comparison between the xience prime cobalt chromium stent and the promus premier platinum chromium stent

2017 ◽  
Vol 91 (3) ◽  
pp. E21-E28 ◽  
Author(s):  
Rutger J. van Bommel ◽  
Miguel E. Lemmert ◽  
Nicolas M. van Mieghem ◽  
Robert-Jan van Geuns ◽  
Ron T. van Domburg ◽  
...  
Keyword(s):  
Cobalt Chromium ◽  
Cobalt Chromium Stent

scholarly journals Testing bioresorbable stent feasibility in a rat aneurysm model

2019 ◽  
Vol 11 (10) ◽  
pp. 1050-1054 ◽  
Author(s):  
Basil Erwin Grüter ◽  
Dominik Täschler ◽  
Fabio Strange ◽  
Jeannine Rey ◽  
Michael von Gunten ◽  
...  
Keyword(s):  
Inflammatory Responses ◽  
Treatment Options ◽  
Cerebral Aneurysms ◽  
Parent Artery ◽  
Cobalt Chromium ◽  
Inflammatory Reactions ◽  
Male Wistar Rats ◽  
Bioresorbable Stent ◽  
Cobalt Chromium Stent ◽  
Aneurysm Model

BackgroundAdvances in stent-assisted coiling have incrementally expanded endovascular treatment options for complex cerebral aneurysms. After successful coil consolidation and aneurysm occlusion, endovascular scaffolds are no longer needed. Thus, bioresorbable stents that disappear after aneurysm healing could avoid future risks of in-stent thrombosis and the need for lifelong antiplatelet therapy.ObjectiveTo assess the applicability and compatibility of a bioresorbable magnesium- alloy stent (brMAS) for assisted coiling.MethodsSaccular sidewall aneurysms were created in 84 male Wistar rats and treated with brMAS alone, brMAS + aspirin, or brMAS + coils + aspirin. Control groups included no treatment (natural course), solely aspirin treatment, or conventional cobalt–chromium stent + coils + aspirin treatment. After 1 and 4 weeks, aneurysm specimens were harvested and macroscopically, histologically, and molecularly examined for healing, parent artery perfusion status, and inflammatory reactions. Stent degradation was monitored for up to 6 months with micro-computed and optical coherence tomography.ResultsAneurysms treated with brMAS showed advanced healing, neointima formation, and subsequent stent degradation. Additional administration of aspirin sustained aneurysm healing while reducing stent-induced intraluminal and periadventitial inflammatory responses. No negative interaction was detected between platinum coils and brMAS. Progressive brMAS degradation was confirmed.ConclusionsbrMAS induced appropriate healing in this sidewall aneurysm model. The concept of using bioresorbable materials to promote complete aneurysm healing and subsequent stent degradation seems promising. These results should encourage further device refinements and clinical evaluation of this treatment strategy for cerebrovascular aneurysms.

Randomized comparative trial of a thin-strut bare metal cobalt-chromium stent versus a sirolimus-eluting stent for coronary revascularization

2007 ◽  
Vol 69 (6) ◽  
pp. 790-798 ◽  
Author(s):  
Paolo Ortolani ◽  
Antonio Marzocchi ◽  
Cinzia Marrozzini ◽  
Tullio Palmerini ◽  
Francesco Saia ◽  
...  
Keyword(s):  
Coronary Revascularization ◽  
Comparative Trial ◽  
Bare Metal ◽  
Cobalt Chromium ◽  
Cobalt Chromium Stent ◽  
Sirolimus Eluting Stent

Treatment of intracranial atherosclerotic arterial stenoses with a balloon-expandable cobalt chromium stent (Coroflex Blue): procedural safety, efficacy, and midterm patency

2009 ◽  
Vol 52 (7) ◽  
pp. 645-651 ◽  
Author(s):  
Zsolt Vajda ◽  
Elina Miloslavski ◽  
Thomas Güthe ◽  
Elisabeth Schmid ◽  
Christoph Schul ◽  
...  
Keyword(s):  
Cobalt Chromium ◽  
Cobalt Chromium Stent ◽  
Arterial Stenoses

Neointimal hyperplasia in a thin-strut cobalt–chromium stent: Insights from detailed 3-D intravascular ultrasound analysis

2010 ◽  
Vol 145 (1) ◽  
pp. 125-126 ◽  
Author(s):  
Hiromasa Otake ◽  
Junya Ako ◽  
Katsuhisa Waseda ◽  
Ryota Sakurai ◽  
Atsushi Hirohata ◽  
...  
Keyword(s):  
Intravascular Ultrasound ◽  
Neointimal Hyperplasia ◽  
Cobalt Chromium ◽  
Cobalt Chromium Stent

scholarly journals Time Course of Reendothelialization of Stents in a Normal Coronary Swine Model

2011 ◽  
Vol 48 (6) ◽  
pp. 1109-1117 ◽  
Author(s):  
A. Pérez de Prado ◽  
C. Pérez-Martínez ◽  
C. Cuellas-Ramón ◽  
J. Manuel Gonzalo-Orden ◽  
M. Regueiro-Purriños ◽  
...  
Keyword(s):  
Time Course ◽  
Cell Types ◽  
Percutaneous Transluminal Coronary Angioplasty ◽  
Giant Cells ◽  
Swine Model ◽  
Cobalt Chromium ◽  
Drug Eluting ◽  
Late Thrombosis ◽  
Cobalt Chromium Stent ◽  
Transluminal Coronary Angioplasty

Late thrombosis of coronary drug-eluting stents is an infrequent but serious complication of percutaneous transluminal coronary angioplasty. The best predictor of this event is the lack of endothelialization of stent struts. The objective of this study is to characterize and quantify the time course of endothelialization of different stents implanted in nonatherosclerotic swine coronary arteries. Thirty-three Carbofilm-coated stents were implanted percutaneously in 11 anesthetized domestic, crossbred pigs (weight 25 ± 3 kg, 2 months old). Each animal received 1 stainless steel stent (SS), 1 cobalt-chromium stent (CCS), and 1 tacrolimus-eluting stent (TES) in each coronary artery. Follow-up periods were 1 day (n = 9 stents), 3 days (n = 9 stents), and 7 days (n = 15 stents). Longitudinal sections of the stented vessels were examined using scanning electron microscopy. At 1 day, there was scarce, patchy endothelialization with areas of fibrin; the endothelialization rate was similar for all the stents (SS, 29% ± 23%; CCS, 29% ± 24%; TES, 31% ± 25%; P = .9). At 3 days, there were more endothelial cells but with immature features and giant cells over fibrin; the endothelialization was greater in SS and CCS than in TES (SS, 79% ± 14%; CCS, 81% ± 17%; TES, 46% ± 9%; P = .007). At 7 days, arteries showed better endothelialization with few giant cells; the endothelialization was greater in SS and CCS than in TES (SS, 95% ± 4%; CCS, 98% ± 4%; TES, 79% ± 9%; P = .01). In conclusion, the described model is useful for the analysis of endothelialization of coronary stents and facilitates measurement of its rate of formation and characterization of the involved cell types.

scholarly journals Comparative Evaluation of Stainless Steel Stent (Sirolimus) and Cobalt Chromium Stent (Sirolimus) In Patient with Coronary Artery Disease

2016 ◽  
Vol 8 (04) ◽  
Author(s):  
J. Shah ◽  
J. Patel ◽  
S. Dani
Keyword(s):  
Coronary Artery Disease ◽  
Stainless Steel ◽  
Coronary Artery ◽  
Coronary Intervention ◽  
Cobalt Chromium ◽  
Cardiac Events ◽  
Target Vessel Revascularization ◽  
Adverse Cardiac Events ◽  
Cobalt Chromium Stent ◽  
Artery Disease

Coronary Artery Disease (CAD) occurs when the arteries of the heart that normally provide blood and oxygen to the heart are narrowed or even completely blocked due to clot formation. The Stenting implantation composes 84.2% of all Percutaneous coronary intervention (PCI). Despite the widespread use of these devices, bare metal stents (BMS) have been associated with a 20-30% restenosis rate which requires reintervention. In December 2006, US Food and Drug Administration cardiovascular experts concluded that for many patients, such as those with uncomplicated medical histories who undergo elective stenting of simple coronary blockages, drug-eluting stents remain a safe and appropriate therapy. Previously reports are suggestive of similar clinical outcomes for stainless steel and cobalt chromium bare metal stent. No reports are available for comparison of sirolimus eluting stainless steel stent and sirolimus eluting cobalt chromium stent. The present study was undertaken with the objective of comparative evaluation of Stainless Steel Stent (Sirolimus) and Cobalt Chromium Stent (Sirolimus) in Patient with Coronary Artery Disease. A single centric, retrospective, nonrandomized study involving 118 patients who have undergone PCI from January 2011 to March 2012 implanted with either Sirolimus Stainless Steel Stent (SSSS) or Sirolimus Cobalt Chromium Stents (SCCS) were included in the study. Primary objective was to determine and compare the clinical outcome and rates of target vessel revascularization (TVR) in patients undergoing primary PCI for CAD patients who were treated with Sirolimus cobalt-chromium stents and Sirolimus stainless steel stents. The secondary outcomes of study were Major Adverse Cardiac Events, mortality at the end of 1 month, 6 month and 1 year of outcomes. At 1 month follow up there was no significant difference between two groups (p = 0.96). The individual clinical component showed no difference in occurrence of death (p = 0.29), MI (p = 0.29) and TLR (p = 0.96) at end of 6 month. The cumulative clinical outcome at 1 year rate of target vessel revascularization TVR (SSSS 1.75% versus SCCS 0%, p = 0.29), target lesion revascularization (SSSS 5.27% versus SCCS 1.63%, p = 0.27), and Major Adverse Cardiac Events (SSSS 22.80% versus SCCS 13.11%, p = 0.16). This study showed that among Coronary artery disease (CAD) patients undergoing primary percutaneous coronary intervention, sirolimus stainless steel stent showed similar efficacy and safety to sirolimus cobalt chromium stent.

Sign in / Sign up

Export Citation Format

Share Document